Berger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock Drop

Core Viewpoint - Rocket Pharmaceuticals is facing a securities class action lawsuit alleging misleading safety disclosures related to its RP-A501 gene therapy program, which has resulted in significant stock price decline following a serious adverse event [1][3]. Company Overview - Rocket Pharmaceuticals is a biotechnology company based in Cranbury, New Jersey, focused on developing gene therapies for rare diseases [2]. Legal Allegations - The lawsuit claims that Rocket Pharmaceuticals did not inform investors about a significant protocol change involving a new immunomodulatory agent before a serious adverse event occurred, leading to a clinical hold by the FDA [3]. - Following the disclosure of a patient death during the trial, Rocket Pharmaceuticals' stock price plummeted nearly 37%, from $6.27 on May 23, 2025, to $2.33 on May 27, 2025 [3]. Investor Information - Investors who purchased Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025, may be eligible to seek recovery, with a lead plaintiff application deadline set for August 11, 2025 [4].